Fulcrum Therapeutics (NASDAQ:FULC) Downgraded by Wall Street Zen to Sell

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities analysts have also issued reports on FULC. Citigroup reaffirmed an “underperform” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Stifel Nicolaus set a $25.00 price target on shares of Fulcrum Therapeutics in a report on Monday, December 8th. JPMorgan Chase & Co. started coverage on shares of Fulcrum Therapeutics in a report on Monday, January 12th. They set an “overweight” rating and a $20.00 price objective for the company. Bank of America lifted their price objective on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research report on Tuesday, December 9th. Finally, Leerink Partners set a $20.00 target price on shares of Fulcrum Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Fulcrum Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $19.11.

Fulcrum Therapeutics Price Performance

NASDAQ FULC opened at $10.14 on Friday. The stock has a market capitalization of $548.78 million, a P/E ratio of -8.59 and a beta of 3.20. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $15.74. The business has a 50 day simple moving average of $10.89 and a 200 day simple moving average of $8.85.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Equities analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Insider Activity

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This represents a 40.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,205,139 shares of company stock valued at $58,711,943 over the last 90 days. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its stake in shares of Fulcrum Therapeutics by 63.5% during the 2nd quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock worth $3,871,000 after purchasing an additional 218,819 shares during the last quarter. Strs Ohio purchased a new position in Fulcrum Therapeutics in the first quarter valued at about $263,000. Bailard Inc. bought a new position in Fulcrum Therapeutics in the second quarter worth about $185,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Fulcrum Therapeutics by 57.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock valued at $2,357,000 after buying an additional 124,798 shares during the last quarter. Finally, Aberdeen Group plc bought a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at about $404,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.